<DOC>
	<DOCNO>NCT02797821</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) pharmacodynamics ( PD ) asfotase alfa adult patient pediatric-onset HPP .</brief_summary>
	<brief_title>Pharmacokinetic , Dose Response Study Asfotase Alfa Adult Patients With Pediatric-Onset Hypophosphatasia ( HPP )</brief_title>
	<detailed_description />
	<mesh_term>Hypophosphatasia</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1 . Patients must ≥18 year age Screening 2 . Patient pediatriconset HPP , define onset first sign ( ) /symptom ( ) HPP prior 18 year age 3 . Patients must document diagnosis HPP indicate documented history HPPrelated skeletal abnormality 1 follow : Documented TNSALP gene mutation ( ) certify laboratory Serum ALP level ageadjusted normal range AND plasma PLP upper limit normal Screening . 4 . Patients must plasma PPi level ≥3.9 µM Screening 5 . Female patient childbearing potential must negative pregnancy test time enrollment 6 . Sexually active male female patient childbearing potential must agree use highly effective method birth control study . 1 . Currently enrol clinical study involve another study drug nonapproved use drug device . 2 . Participated , within last 30 day , clinical study involve study drug ( study drug use study ) . 3 . Have complete withdrawn study study investigate asfotase alfa previous 3 year . 4 . Women pregnant , plan become pregnant , breastfeed 5 . Serum 25OH Vitamin D 20 ng/mL Screening 6 . Screening serum creatinine parathyroid hormone ( PTH ) level 1.5 time upper limit normal 7 . Any medical condition , serious concurrent illness and/or injury , opinion Investigator , may significantly interfere study compliance study endpoint . 8 . Prior treatment bisphosphonates within 2 year study entry length time 2 consecutive year prior timepoint 9 . Treatment PTH , strontium , sclerostin inhibitor within 6 month prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HPP</keyword>
	<keyword>asfotase alfa</keyword>
</DOC>